Chemotherapy continues to be an essential method in the treatment of cancer, and increased research is enhancing its efficacy while reducing side effects. The lecture "Chemotherapy Advances" highlights the most recent advances in drug design, delivery routes, and combination therapies that maximize patient benefit.
Current chemotherapy has changed from non-selective cytotoxic agents to more specific agents that target cancer cells selectively. Trends in formulation and delivery, such as nanoparticle-based systems and controlled-release technology, are enhancing drug bioavailability and diminishing toxicity to normal tissues. Combination regimens involving chemotherapy with targeted therapy, immunotherapy, or radiation are becoming popular to circumvent resistance and enhance the response to therapy.
Session also discusses individualized chemotherapy approaches based on genetic profiling and biomarkers. They assist physicians in selecting the most appropriate drugs for an individual patient, tracking response to treatment, and making changes to regimens in real-time. Moreover, investigation into drug resistance mechanisms and supportive care strategies is improving the quality of life of patients during treatment.
Participants will learn about the latest and new approaches in chemotherapy, clinical uses, and novel research that defines the future of oncology treatment. This session highlights the need for precision, personalization, and multidisciplinary care in optimizing the benefits of chemotherapy and reducing the risk.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
